Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations
After your last dose, significant levels remain in your system for weeks
doi: 10.1002/dmrr.3070 Summary Keywords GLP-1 receptor agonists, thyroid disorders, thyroid cancer, meta-analysis, randomized controlled trials Citation Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X and Liu J (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
Study author Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford, summarized the findings to to Medical News Today , saying: We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss. Overall, semaglutide was linked to a bigger decrease in BMI
Beyond numbers, the advantages of Zepbound expand into increased energy, alleviated joint pain, better sleep, heightened self-esteem, and decreased risks for heart disease and diabetes
Integrating ICD-10 Coding with DocVillas EHR/EMR Software Implementing accurate ICD-10 coding can be complex, but DocVillas EHR and EMR software simplifies this process for weight loss clinics
